Article Figures & Data
Figures
- FIGURE 1.
Study design.
- FIGURE 2.
Biodistribution of 11C-sorafenib in different healthy tissues and tumor tissue. PRE = baseline; POST = after 14 d of sorafenib therapy.
- FIGURE 3.
Fusion 11C-sorafenib PET/CT (sum, 40–60 min), low-dose CT, and PET images from 3 patients showing 11C-sorafenib uptake in tumor lesions (arrows). Patient A, with hepatocellular carcinoma, has metastasis in left costa 4; patient B, with renal cell carcinoma, has metastasis in left adrenal gland; and patient C, with hepatocellular carcinoma, has large intraabdominal metastasis. Physiologic uptake can be seen in liver (*) and kidneys (Δ).
- FIGURE 4.
Tumor 11C-sorafenib VT on days 0 (A) and 14 (B) in lesions of patients with progressive disease (PD) and stable disease (SD).
- FIGURE 5.
Correlation between tumor 11C-sorafenib VT and tumor sorafenib concentration (A) or sorafenib tumor-to-plasma ratio (B) measured with LC-MS/MS.
- FIGURE 6.
(A) Correlation between tumor 11C-sorafenib VT and perfusion of tumor rim. (B) Tumor perfusion difference after 14 d of sorafenib treatment in patients with PD and SD.
Tables
- TABLE 1
Tumor and Plasma Sorafenib Concentrations Measured with LC-MS/MS and 11C-Sorafenib Tumor VT on Days 0 and 14
VT Patient Age (y) Sex Tumor Biopsy site Tumor (μg/L) Plasma (μg/L) Tumor-to-plasma ratio Day 0 Day 14 Response 1 52 F DTC Skin 3,390 6,100 0.56 0.72 0.27 PD 2 55 M RCC Spleen 3,480 4,860 0.72 0.40 0.23 PD 3 59 M RCC Adrenal gland 5,700 6,880 0.83 0.33 0.11 SD 4 69 M HCC — — 6,180 — 1.52 — PD 5 66 M RCC Lung 11,750 9,610 1.22 0.34 0.10 SD 6 60 F RCC Adrenal gland 3,000 6,490 0.46 2.11 0.71 PD 7 66 M HCC Liver 13,400 6,860 1.95 1.26 0.28 PD 8 59 M RCC Lung 13,200 7,550 1.75 0.14 0.26 PD DTC = differentiated thyroid carcinoma; PD = progressive disease; RCC = renal cell carcinoma; SD = stable disease; HCC = hepatocellular carcinoma.
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- No citing articles found.